SCOPUS 정보 검색 플랫폼

Volumn 117, Issue 10, 2011, Pages 2077-2085

Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer

(4) Smith, Matthew R a Cook, Richard b Lee, Ker Ai b Nelson, Joel B c

a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER (United States)

b UNIVERSITY OF WATERLOO (Canada)

c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE (United States)

Author keywords

androgen deprivation therapy; bone metastases; prostate cancer; prostate specific antigen

Indexed keywords

ALBUMIN; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; BONE METABOLISM; BONE METASTASIS; CANCER MORTALITY; CANCER SURVIVAL; CASTRATION RESISTANT NONMETASTATIC PROSTATE CANCER; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GLEASON SCORE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BODY MASS INDEX; BONE NEOPLASMS; CASTRATION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 79955494424 PISSN: 0008543X EISSN: 10970142 Source Type: Journal
DOI: 10.1002/cncr.25762 Document Type: Article

Times cited : (155)

References (28)

1
- 4744337716
- Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
- DOI 10.1056/NEJMoa041318
- Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-1520. (Pubitemid 39315318)
- (2004) New England Journal of Medicine , vol.351 , Issue.15 , pp. 1513-1520
- Petrylak, D.P.¹ Tangen, C.M.² Hussain, M.H.A.³ Lara Jr., P.N.⁴ Jones, J.A.⁵ Taplin, M.E.⁶ Burch, P.A.⁷ Berry, D.⁸ Moinpour, C.⁹ Kohli, M.¹⁰ Benson, M.C.¹¹ Small, E.J.¹² Raghavan, D.¹³ Crawford, E.D.¹⁴

2
- 4744366279
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
- DOI 10.1056/NEJMoa040720
- Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512. (Pubitemid 39315317)
- (2004) New England Journal of Medicine , vol.351 , Issue.15 , pp. 1502-1512
- Tannock, I.F.¹ De Wit, R.² Berry, W.R.³ Horti, J.⁴ Pluzanska, A.⁵ Chi, K.N.⁶ Oudard, S.⁷ Theodore, C.⁸ James, N.D.⁹ Turesson, I.¹⁰ Rosenthal, M.A.¹¹ Eisenberger, M.A.¹²

3
- 22144484150
- Androgen deprivation therapy for prostate cancer
- DOI 10.1001/jama.294.2.238
- Sharifi N, Gulley JL, Dahut WL., Androgen deprivation therapy for prostate cancer. JAMA. 2005; 294: 238-244. (Pubitemid 41043794)
- (2005) Journal of the American Medical Association , vol.294 , Issue.2 , pp. 238-244
- Sharifi, N.¹ Gulley, J.L.² Dahut, W.L.³

4
- 21144438189
- Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
- DOI 10.1200/JCO.2005.01.529
- Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005; 23: 2918-2925. (Pubitemid 46224110)
- (2005) Journal of Clinical Oncology , vol.23 , Issue.13 , pp. 2918-2925
- Smith, M.R.¹ Kabbinavar, F.² Saad, F.³ Hussain, A.⁴ Gittelman, M.C.⁵ Bilhartz, D.L.⁶ Wynne, C.⁷ Murray, R.⁸ Zinner, N.R.⁹ Schulman, C.¹⁰ Linnartz, R.¹¹ Zheng, M.¹² Goessl, C.¹³ Hei, Y.-J.¹⁴ Small, E.J.¹⁵ Cook, R.¹⁶ Higano, C.S.¹⁷

5
- 1442265961
- Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy
- DOI 10.1200/JCO.2004.03.132
- Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004; 22: 439-445. (Pubitemid 41079772)
- (2004) Journal of Clinical Oncology , vol.22 , Issue.3 , pp. 439-445
- Amling, C.L.¹ Riffenburgh, R.H.² Sun, L.³ Moul, J.W.⁴ Lance, R.S.⁵ Kusuda, L.⁶ Sexton, W.J.⁷ Soderdahl, D.W.⁸ Donahue, T.F.⁹ Foley, J.P.¹⁰ Chung, A.K.¹¹ McLeod, D.G.¹²

6
- 1442290398
- Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: A report by the shared equal access regional cancer hospital database study group
- DOI 10.1200/JCO.2004.04.181
- Freedland SJ, Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004; 22: 446-453. (Pubitemid 41079773)
- (2004) Journal of Clinical Oncology , vol.22 , Issue.3 , pp. 446-453
- Freedland, S.J.¹ Aronson, W.J.² Kane, C.J.³ Presti Jr., J.C.⁴ Amling, C.L.⁵ Elashoff, D.⁶ Terris, M.K.⁷

7
- 33746313572
- Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer
- DOI 10.1002/cncr.22025
- Strom SS, Kamat AM, Gruschkus SK, et al. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer. 2006; 107: 631-639. (Pubitemid 44107225)
- (2006) Cancer , vol.107 , Issue.3 , pp. 631-639
- Strom, S.S.¹ Kamat, A.M.² Gruschkus, S.K.³ Gu, Y.⁴ Wen, S.⁵ Cheung, M.R.⁶ Pisters, L.L.⁷ Lee, A.K.⁸ Rosser, C.J.⁹ Kuban, D.A.¹⁰

8
- 37049016720
- Obesity and mortality in men with locally advanced prostate cancer: Analysis of RTOG 85-31
- DOI 10.1002/cncr.23093
- Efstathiou JA, Bae K, Shipley WU, et al. Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer. 2007; 110: 2691-2699. (Pubitemid 350250338)
- (2007) Cancer , vol.110 , Issue.12 , pp. 2691-2699
- Efstathiou, J.A.¹ Bae, K.² Shipley, W.U.³ Hanks, G.E.⁴ Pilepich, M.V.⁵ Sandler, H.M.⁶ Smith, M.R.⁷

9
- 0034660097
- Markers of bone turnover in bone metastases
- Fontana A, Delmas PD., Markers of bone turnover in bone metastases. Cancer. 2000; 88: 2952-2960. (Pubitemid 30413178)
- (2000) Cancer , vol.88 , Issue.12 SUPPL. , pp. 2952-2960
- Fontana, A.¹ Delmas, P.D.²

10
- 0035022942
- Markers of bone turnover in prostate cancer
- DOI 10.1053/ctrv.2000.0213
- Garnero P., Markers of bone turnover in prostate cancer. Cancer Treat Rev. 2001; 27: 187-192; discussion 193-196. (Pubitemid 32452020)
- (2001) Cancer Treatment Reviews , vol.27 , Issue.3 , pp. 187-192
- Garnero, P.¹

11
- 0036789479
- Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration
- Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002; 20: 3972-3982.
- (2002) J Clin Oncol , vol.20 , pp. 3972-3982
- Smaletz, O.¹ Scher, H.I.² Small, E.J.³

12
- 0038514138
- Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
- DOI 10.1200/JCO.2003.06.100
- Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003; 21: 1232-1237. (Pubitemid 46606398)
- (2003) Journal of Clinical Oncology , vol.21 , Issue.7 , pp. 1232-1237
- Halabi, S.¹ Small, E.J.² Kantoff, P.W.³ Kattan, M.W.⁴ Kaplan, E.B.⁵ Dawson, N.A.⁶ Levine, E.G.⁷ Blumenstein, B.A.⁸ Vogelzang, N.J.⁹

13
- 33745203917
- Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer
- Cook RJ, Coleman R, Brown J, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2006; 12: 3361-3367.
- (2006) Clin Cancer Res , vol.12 , pp. 3361-3367
- Cook, R.J.¹ Coleman, R.² Brown, J.³

14
- 69049105440
- Denosumab in men receiving androgen-deprivation therapy for prostate cancer
- Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009; 361: 745-755.
- (2009) N Engl J Med , vol.361 , pp. 745-755
- Smith, M.R.¹ Egerdie, B.² Hernandez Toriz, N.³

15
- 69249206543
- The critical role of the bone microenvironment in cancer metastases
- Casimiro S, Guise TA, Chirgwin J., The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol. 2009; 310: 71-81.
- (2009) Mol Cell Endocrinol , vol.310 , pp. 71-81
- Casimiro, S.¹ Guise, T.A.² Chirgwin, J.³

16
- 55549112219
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer
- Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008; 113: 2478-2487.
- (2008) Cancer , vol.113 , pp. 2478-2487
- Nelson, J.B.¹ Love, W.² Chin, J.L.³

17
- 85088938629
- 2nd ed. New York, NY: John Wiley and Sons.
- Kalbfleisch J, Prentice R, The Statistical Analysis of Failure Time Data. 2nd ed. New York, NY: John Wiley and Sons; 2002.
- (2002) The Statistical Analysis of Failure Time Data
- Kalbfleisch, J.¹ Prentice, R.²

18
- 0003570192
- New York, NY: Springer-Verlag.
- Therneau RM, Grambsch PM,: Modeling Survival Data: Extending the Cox Model. New York, NY: Springer-Verlag; 2000.
- (2000) Modeling Survival Data: Extending the Cox Model
- Therneau, R.M.¹ Grambsch, P.M.²

19
- 0031014008
- Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations
- Lee WR, Hanks GE, Hanlon A., Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol. 1997; 15: 230-238. (Pubitemid 27020578)
- (1997) Journal of Clinical Oncology , vol.15 , Issue.1 , pp. 230-238
- Lee, W.R.¹ Hanks, G.E.² Hanlon, A.³

20
- 0030815150
- Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen
- DOI 10.1016/S0022-5347(01)64238-1
- Patel A, Dorey F, Franklin J, et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997; 158: 1441-1445. (Pubitemid 27391215)
- (1997) Journal of Urology , vol.158 , Issue.4 , pp. 1441-1445
- Patel, A.¹ Dorey, F.² Franklin, J.³ Dekernion, J.B.⁴

21
- 0030857412
- Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy
- DOI 10.1016/S0360-3016(97)00082-5, PII S0360301697000825
- Sartor CI, Strawderman MH, Lin XH, et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 1997; 38: 941-947. (Pubitemid 27353672)
- (1997) International Journal of Radiation Oncology Biology Physics , vol.38 , Issue.5 , pp. 941-947
- Sartor, C.I.¹ Strawderman, M.H.² Lin, X.-H.³ Kish, K.E.⁴ McLaughlin, P.W.⁵ Sandler, H.M.⁶

22
- 0033526309
- Natural history of progression after PSA elevation following radical prostatectomy
- DOI 10.1001/jama.281.17.1591
- Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281: 1591-1597; comment 1642-1645. (Pubitemid 29211767)
- (1999) Journal of the American Medical Association , vol.281 , Issue.17 , pp. 1591-1597
- Pound, C.R.¹ Partin, A.W.² Eisenberger, M.A.³ Chan, D.W.⁴ Pearson, J.D.⁵ Walsh, P.C.⁶

23
- 0034307224
- Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy
- Sandler HM, Dunn RL, McLaughlin PW, et al. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2000; 48: 629-633.
- (2000) Int J Radiat Oncol Biol Phys , vol.48 , pp. 629-633
- Sandler, H.M.¹ Dunn, R.L.² McLaughlin, P.W.³

24
- 0036895121
- Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer
- DOI 10.1200/JCO.2002.03.061
- D'Amico AV, Cote K, Loffredo M, et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 2002; 20: 4567-4573. (Pubitemid 35402960)
- (2002) Journal of Clinical Oncology , vol.20 , Issue.23 , pp. 4567-4573
- D'Amico, A.V.¹ Cote, K.² Loffredo, M.³ Renshaw, A.A.⁴ Schultz, D.⁵

25
- 0141729468
- Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy
- D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003; 95: 1376-1383. (Pubitemid 37220457)
- (2003) Journal of the National Cancer Institute , vol.95 , Issue.18 , pp. 1376-1383
- D'Amico, A.V.¹ Moul, J.W.² Carroll, P.R.³ Sun, L.⁴ Lubeck, D.⁵ Chen, M.-H.⁶

26
- 0032211277
- The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: An analysis of cancer and leukemia group B study 9181 of megestrol acetate
- DOI 10.1002/(SICI)1097-0142(19981101)83:9<1989::AID-CNCR15>3.0. CO;2-V
- Vollmer RT, Dawson NA, Vogelzang NJ., The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate. Cancer. 1998; 83: 1989-1994. (Pubitemid 28503731)
- (1998) Cancer , vol.83 , Issue.9 , pp. 1989-1994
- Vollmer, R.T.¹ Dawson, N.A.² Vogelzang, N.J.³

27
- 33646235166
- Markers of bone metabolism in prostate cancer
- (suppl 1).
- Smith MR., Markers of bone metabolism in prostate cancer. Cancer Treat Rev. 2006; 32 (suppl 1): 23-26.
- (2006) Cancer Treat Rev , vol.32 , pp. 23-26
- Smith, M.R.¹

28
- 26444519930
- Obesity and prostate cancer: A growing problem
- DOI 10.1158/1078-0432.CCR-05-1305
- Freedland SJ., Obesity and prostate cancer: a growing problem. Clin Cancer Res. 2005; 11: 6763-6766. (Pubitemid 41428728)
- (2005) Clinical Cancer Research , vol.11 , Issue.19 , pp. 6763-6766
- Freedland, S.J.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.